[BRKRP] Bruker: Q3 2026 earnings preview on orders, chip metrology and margins

Bruker is a US maker of high-end scientific instruments, including nuclear magnetic resonance (NMR) spectrometers, mass spectrometers, X-ray microscopy systems and semiconductor metrology tools. The Drillr earnings calendar lists 2026-10-29 for its results covering the quarter ended September 30, 2026 (2026 年三季度(截至 2026 年 9 月 30 日)), but the same calendar shows 2026-11-02 for the BRKR common-stock line, and as of October 20 the company had not announced a date[1]. In the latest disclosed quarter, the second quarter of 2026, revenue rose 5.2% to $838.5 million, with organic growth of 2.8%; the non-GAAP operating margin climbed to 14.1% from 9.0% a year earlier and non-GAAP EPS was $0.49, but a $134.9 million goodwill impairment produced a GAAP loss of $0.41 per share[2]. On the August 4 earnings call, management said about $20 million of semiconductor revenue would move from the third quarter to the fourth, leaving third-quarter organic revenue roughly flat to slightly up and non-GAAP operating margin and EPS slightly below the second quarter[3]; the company kept full-year guidance of $3.54 billion to $3.57 billion in revenue and $2.10 to $2.15 in non-GAAP EPS[2]. Analyst forecasts compiled by Drillr average $865.2 million in third-quarter revenue (6 analysts, range $864.0 million to $866.3 million) and $0.42 in non-GAAP EPS (8 analysts)[4], with full-year EPS averaging $2.12[5].

Three things matter most in this Bruker Q3 2026 earnings report. The first is whether organic revenue stays positive: scientific-instrument organic orders grew 10% in the second quarter, yet US academic and government revenue fell by more than $15 million year over year, so the third quarter is the first test of whether better orders can offset weak US academic demand[6][7]. The second is the timing of semiconductor metrology deliveries: this business grew organic orders by more than 30% in the first half at an EBIT margin of about 30%, about $20 million of its revenue has already slipped into the fourth quarter, and the company's expectation of roughly $1 billion in fourth-quarter revenue depends on these deliveries, so any further slippage in the third quarter bears directly on the full-year profit path[8][3]. The third is the margin after tariff refunds: about 200 basis points of the second quarter's 14.1% non-GAAP operating margin came from tariff benefits recognized early, and where the third-quarter margin lands will show how much of the $140 million cost program actually stays on the income statement[7][6].

Company Background and Business Structure

Bruker is headquartered in Billerica, Massachusetts, and its common stock trades on Nasdaq under BRKR[9]. In September 2025 the company issued 2.76 million shares of 6.375% Series A mandatory convertible preferred stock, the BRKRP line in this article's title[10]; the preferred carries a $693.6 million liquidation preference and will automatically convert on September 1, 2028 into between 6.9534 and 8.5179 common shares per preferred share[11]. The company develops, manufactures and sells high-performance scientific instruments and analytical and diagnostic solutions that customers use to study life and materials at the molecular, cellular and microscopic levels[12]. Bruker's 2025 revenue was $3.4365 billion[13], it had about 11,085 employees at year-end with about 20.2% in the United States[14], and no single customer accounted for more than 10% of revenue in the past three years[15].

In 2025 the company reported four segments whose size and direction differed sharply. BSI BioSpin, built on magnetic resonance, had revenue of $878.8 million, down 3.0%, mainly because it shipped only two GHz-class NMR systems versus four in 2024; BSI CALID, covering mass spectrometry, spectroscopy, microbial identification, molecular diagnostics and security detection, grew 10.7% to $1.2102 billion, driven mainly by ELITechGroup, acquired in 2024, and by security detection and the MALDI Biotyper business[16]. BSI NANO, covering X-ray, atomic force microscopy, semiconductor metrology and the spatial biology business formed by the 2024 NanoString acquisition, had revenue of $1.0843 billion, down 1.3%; BEST, which makes low-temperature superconducting wire and supplies equipment for fusion and high-energy physics research, had revenue of $270.9 million[16].

Bruker's revenue is mostly equipment and its production is concentrated in its own plants, which shapes both its delivery rhythm and its cost structure. In 2025 product revenue was $2.7664 billion and service and other revenue was $670.1 million, so equipment was roughly 80% of the total[13]; plants in Europe, Israel and California handle every step from machining to final testing, and critical components are made in-house[17]. Sales cycles typically run three to 24 months for academic and high-end research products and two weeks to six months for industrial products[18], and fourth-quarter revenue has historically been stronger than the first three quarters[19]. From the third quarter of 2026 the company reports four new segments: BIOS (combining the former BioSpin, SciY, Chemspeed, Daltonics mass spectrometry and Optics), BMID (microbiology and infection diagnostics), NANO and BEST[20], so the third-quarter report will be the first under the new structure.

Financial History and Current Position

In 2025 acquisitions kept Bruker's revenue growing slightly while profit fell sharply. Revenue rose 2.1% from $3.3664 billion in 2024 to $3.4365 billion[13], but organic revenue fell 3.7%[21], and growth came mainly from the ELITechGroup and NanoString acquisitions[16]. GAAP gross margin fell from 49.0% to 45.9%[22], and GAAP operating income dropped from $253.1 million to $68.2 million, including $77.4 million of restructuring costs and $127.2 million of goodwill and intangible impairments[23]; net income attributable to the company was negative $8.6 million, and after preferred dividends the loss attributable to common shareholders was $22.5 million[13].

On the company's adjusted basis, 2025 margins and cash flow also weakened. Non-GAAP gross margin fell from 51.6% to 49.8% and non-GAAP operating margin fell from 15.4% to 12.6%[21], while non-GAAP EPS was $1.83[2]. Operating cash flow was $134.1 million and capital spending was $90.8 million, leaving free cash flow of only $43.3 million, down from $136.0 million in 2024[23].

In the first half of 2026 revenue grew again, but organic recovery only appeared in the second quarter. First-quarter revenue rose 2.7% to $823.4 million, organic revenue fell 4.4%, and the non-GAAP operating margin dropped from 12.7% to 10.2%[24]. Organic growth turned to 2.8% in the second quarter; first-half revenue rose 3.9% to $1.6619 billion with an organic decline of 0.8%, the first-half non-GAAP operating margin improved from 10.9% to 12.2%, and non-GAAP EPS was $0.80 versus $0.78 a year earlier[2].

On the balance sheet, cash is shrinking while borrowings and backlog are growing. Cash was $184.9 million at the end of June, down from $298.8 million at the start of the year[25]; total debt was $1.8248 billion, including a $170.0 million revolving loan that did not exist at year-end[26]. Remaining performance obligations (RPO) rose from $2.5694 billion at the start of the year to $2.7756 billion[27], and first-half free cash flow was negative $59.2 million[28]. In August the company updated its full-year outlook only for currency and tax, keeping organic growth guidance of 1% to 2% and non-GAAP EPS guidance of $2.10 to $2.15[2].

Operating Model

Bruker's revenue is set by orders, delivery timing and currency, and changes in orders usually take several quarters to show up as revenue. Revenue equals equipment product revenue plus service revenue, and service and other revenue grew 10.4% in 2025, making it far steadier than equipment[13]. Once a customer orders, the order enters remaining performance obligations and is recognized as revenue according to production, installation and customer site readiness[27], with cycles for academic and high-end research equipment running as long as 24 months[18]. Reported revenue then breaks into organic growth, acquisitions and currency: second-quarter reported growth of 5.2%, for example, consisted of 2.8% organic, 1.5% from acquisitions and 0.9% from currency[28]. By geography, second-quarter revenue was $248.2 million in the United States, $308.7 million in Europe and $217.3 million in Asia Pacific, where revenue fell year over year[29].

Profit is set by gross margin and expense ratios, and gross margin is most sensitive to product mix, tariffs and currency. Non-GAAP operating income equals revenue times non-GAAP gross margin, less selling, general and administrative (SG&A) and research and development expenses; in the second quarter the non-GAAP gross margin was 52.1%, non-GAAP SG&A was $223.9 million, and non-GAAP operating income was $118.5 million, a 14.1% margin[30]. On a GAAP basis, SG&A was 28.5% of second-quarter revenue, as cost savings were offset by acquisitions, currency and inflation[31]; the gross margin improvement came from cost savings, net tariff benefits, higher revenue and product mix[32]. Expenses are being reduced by an annualized $140 million cost program[6], while GAAP profit also absorbs second-quarter amortization of acquired intangibles of $33.3 million and the $134.9 million goodwill impairment[30]; the company calculates non-GAAP EPS at a tax rate of about 27.5%[2], and preferred dividends are deducted from profit attributable to common shareholders[11].

Cash conversion depends on working capital tied up in long-lead instruments, and it swings far more than profit. Free cash flow equals net income plus depreciation, impairments and other non-cash items, less the increase in working capital and capital spending; at the end of June inventory was $1.1201 billion and receivables were $545.9 million, partly offset by $444.6 million in the current portion of customer advances and deferred revenue[25]. Free cash flow was $43.3 million in 2025[23] and negative $59.2 million in the first half of 2026[28], a period that included patent settlement payments to AbCellera and 10x Genomics[33]. The main call on cash is the preferred dividend, which at a 6.375% annual rate on the $693.6 million liquidation preference comes to about $44 million a year[11]; any shortfall is covered by a revolving credit facility of up to $900 million[34], of which $170.0 million was drawn at the end of June[26].

Industry and Competitive Position

Bruker faces different rivals in each niche, and many are much larger. Its annual report names JEOL and Oxford Instruments among the main NMR competitors; in mass spectrometry and spectroscopy for life science and applied markets, competitors include Danaher, Agilent, Waters, Thermo Fisher Scientific and Shimadzu, and in microbial identification it faces bioMérieux[15]. In X-ray, microscopy and spatial biology, competitors include Rigaku, Oxford Instruments, Zeiss and 10x Genomics, while in low-temperature superconducting wire it competes with Western Superconducting Technologies, Luvata and Jastec[15].

The company differentiates itself through high-end, customized research instruments, and the cost is heavy dependence on research budget cycles. In 2025 US revenue was $891.3 million, or 25.9% of the total, and China revenue was $475.8 million, or 13.8%[35]. The annual report says a substantial portion of US revenue comes from academic and government institutions that rely on NIH, NSF and DOE grants, and that funding disruptions in 2025 led these customers to cut or delay purchases[36].

On profitability, Bruker still trails larger peers, but the available comparison is limited. The company's non-GAAP operating margin was only 12.6% in 2025[21], and management's long-term goal is an EBIT margin in the low 20% range[3]. Bruker does not disclose revenue or orders by end market, and no peer margin data that can be checked directly is available here, so the article can only confirm that Bruker's margin is below its own past level and its long-term target, not precisely quantify the gap with larger peers.

Core Debates

With U.S. academic customers still cutting purchases, can new orders from biopharma, non-U.S. academia and security detection sustain organic growth in the third quarter?

This question decides whether Bruker's revenue can break out of its decline. The scientific-instrument business is about 90% of revenue, with second-quarter BSI revenue of $767.3 million[29], and US academic and government research is the customer group most dependent on grants[36]. Organic revenue fell 3.7% in 2025[21] and another 4.4% in the first quarter of 2026[24] before growing 2.8% in the second quarter; management guides to only 1% to 2% organic growth for the full year[2], describes the third quarter as "flat to slightly up," and places most of the growth in roughly $1 billion of fourth-quarter revenue[3].

Orders have improved while the drag on revenue persists, and both readings have support. In the second quarter BSI organic orders grew 10%, the book-to-bill ratio stayed above 1.0 for a fourth straight quarter, and biopharma orders grew more than 20%[6]; academic and government orders grew more than 10% in Europe and more than 20% in China, but US academic and government revenue fell by more than $15 million year over year[7], and Asia Pacific revenue fell 10.2%[37]. Management's explanation is that US academic weakness reflects thin orders in the second half of 2025, and that non-US and biopharma orders will convert to revenue in coming quarters[7]. The alternative reading is that a large share of order growth comes from deep-tech and energy research projects with 9- to 24-month delivery times[6], so near-term revenue still depends on US academic demand, and if that keeps falling the third quarter could come in below "flat."

The baseline and transmission path for this debate are fairly clear. The baselines are second-quarter organic revenue growth of 2.8%, BSI organic order growth of 10% and a US academic and government revenue decline of more than $15 million[2][6][7]. Lower grant funding delays purchases of high-end NMR, mass spectrometry and X-ray systems, while demand from biopharma, hospital and clinical, and security detection customers is growing[38]; those orders enter a backlog of about $2.78 billion and are recognized as BSI organic revenue over delivery periods of three to 24 months, then combined with acquisitions and currency to form reported revenue[27][18].

The third-quarter report needs to show whether better orders have started to turn into revenue. The metrics to watch are whether organic revenue grows year over year and full-year guidance of 1% to 2% holds, whether the BSI book-to-bill ratio stays above 1.0 for a fifth straight quarter, and what management says about US academic orders and Asia Pacific revenue. If organic revenue declines and the cause points to demand rather than delivery timing, better orders have not yet covered US academic weakness; if the book-to-bill ratio falls below 1.0, the backlog's support for later revenue weakens.

Semiconductor metrology orders tied to AI memory and advanced packaging are up more than 30%; will they convert into revenue on schedule?

Semiconductor metrology is one of Bruker's fastest-growing and most profitable businesses, and its delivery timing directly shapes the full-year profit path. Management said semiconductor metrology organic orders grew more than 30% in the first half, revenue grew more than 15%, and the EBIT margin was about 30%[8]. But these tools mostly have lead times of three to eight quarters set by the readiness of customer fabs[7], about $20 million of revenue has already moved from the third quarter to the fourth, and the company's expectation of roughly $1 billion in fourth-quarter revenue relies on these deliveries[3].

Current evidence shows the semiconductor business growing, while the NANO segment as a whole is still held back by other units. NANO second-quarter revenue rose 3.6% to $261.3 million from $252.1 million a year earlier[29], and GAAP gross margin rose from 46.0% to 50.3%[32]; but first-half NANO revenue of $507.3 million was still down low single digits year over year, as weaker academic and industrial demand offset semiconductor growth[8]. Management's explanation is that order visibility covers at least the next six quarters and the revenue delay is only a matter of customer fab readiness[7]. The alternative reading is that the pace of AI-related capital spending is set by a handful of memory and packaging customers, so repeated slippage could push high-margin revenue out of 2026, with nothing in NANO's other businesses growing to fill the gap.

The baselines for this debate are NANO's second-quarter revenue of $261.3 million, its 50.3% gross margin and first-half semiconductor metrology order growth above 30%[29][32][8]. The transmission path runs from memory and advanced packaging makers buying X-ray metrology and defect inspection tools to expand AI chip capacity, to NANO revenue recognized at customer acceptance, which then lifts segment and company margins at an EBIT margin of about 30%. A delivery delay only shifts the quarter of recognition without changing the order itself, but it leaves third-quarter revenue and margin below the second quarter.

The third-quarter report needs to show whether deliveries have slipped further. The specific checks are whether NANO revenue is at least $241.3 million, the second-quarter level less the $20 million shifted out; whether management confirms that the roughly $20 million ships in the fourth quarter and keeps its expectation of about $1 billion in fourth-quarter revenue; and the latest figures on semiconductor metrology order growth and lead times. If deliveries slip into 2027, the fourth-quarter ramp in revenue and margin will not materialize; if NANO gross margin falls below 46%, the higher share of high-margin products has not lasted.

How much of the second-quarter margin jump came from cost cuts, and how much from one-time tariff refunds?

Bruker's 2026 earnings growth rests on margin repair rather than revenue growth. Full-year guidance calls for 250 to 300 basis points of non-GAAP operating margin expansion and 15% to 17% EPS growth on organic revenue growth of only 1% to 2%[3]. The second-quarter non-GAAP operating margin rose to 14.1%, but about 200 basis points of it and 6 cents of EPS came from tariff benefits originally planned for the third quarter[7], so how far the third-quarter margin falls will determine whether the cost savings look structural.

The second-quarter numbers were strong, but the drivers are hard to separate. Non-GAAP gross margin was 52.1%, up 350 basis points, the non-GAAP operating margin was 14.1%, up 510 basis points, and EPS was $0.49; management said it delivered $30 million of savings in the quarter against a full-year annualized target of $140 million[6]. Management's explanation is that cost cuts, tariff refunds and mix drove the gain together, and that the third quarter will dip only slightly because of the semiconductor revenue shift and the early tariff benefit[7]. The alternative reading is that, excluding tariffs, the second-quarter margin was about 12.1%, close to the full-year 2025 level of 12.6%[21]; SG&A as a share of revenue did not fall, as savings were offset by currency, acquisitions and inflation[31], and full-year guidance requires a second-half margin far above the first half, relying on large fourth-quarter deliveries.

The baselines for this debate are the second quarter's 14.1% non-GAAP operating margin, 52.1% non-GAAP gross margin and $0.49 non-GAAP EPS[30]. Headcount reductions, site consolidation and product-line exits lower expenses and manufacturing costs, while the new segment reorganization carries separate restructuring costs of $12 million to $15 million[39]; tariff refunds reduce product costs in the quarter they are approved[40]; euro and Swiss franc costs raise translated expenses when the dollar weakens, and a delivery mix rich in high-priced NMR and semiconductor tools lifts gross margin. The resulting non-GAAP operating income, after interest and a 27.5% non-GAAP tax rate, divided by diluted shares, gives non-GAAP EPS[2].

The third-quarter report needs to show where the margin stands without one-time gains. The key checks are where the non-GAAP operating margin lands relative to 12.0% and 14.1%, whether non-GAAP EPS is at least $0.40 and full-year guidance of $2.10 to $2.15 holds, what management says about progress on the $140 million of savings and the additional $20 million planned for 2027[6], and whether SG&A as a share of revenue starts falling below the prior-year level. If the third-quarter margin is below 12.0%, cost savings have not improved margins once tariffs are excluded; if full-year EPS guidance is cut, the assumption of a fourth-quarter ramp no longer holds.

Was the $100 million second-quarter cash outflow a matter of one-off payments and collection timing, or is working capital persistently tied up in long-lead instruments?

Bruker's non-GAAP EPS is growing but cash is not keeping up, which makes this a question about earnings quality. Free cash flow was only $43.3 million in 2025[23], negative $106.2 million in the second quarter of 2026 and negative $59.2 million for the first half[28]; cash fell from $298.8 million at the start of the year to $184.9 million[25], and the company drew $170.0 million on its revolving credit facility again[26]. The company also pays about $44 million a year in preferred dividends[11], and with no patent settlement payments in the third quarter, it is a clean quarter for testing underlying cash conversion[33].

The cash outflow has one-off causes as well as causes that could persist. Second-quarter operating cash flow was negative $77.4 million, with a working capital change of negative $196.9 million[41]; the 10-Q attributes the first-half working capital deterioration to settlement payments and lower collections of receivables[42], and inventory rose $25.5 million from year-end to $1.1201 billion[25]. In the second quarter the company also recorded $134.9 million of goodwill impairments on its spatial biology (BSB) and Chemspeed reporting units, leaving $174.5 million of goodwill at BSB[43], and the third-quarter segment reorganization triggered a new interim test[44]. Management's explanation is that the settlements are fully paid and large fourth-quarter deliveries will bring in collections; the alternative reading is that long lead times on semiconductor and energy research orders will keep inventory absorbing cash, and that with the fair value of the loss-making spatial biology business already close to its carrying amount, a further impairment would show these acquisitions returning less than expected.

The baselines for this debate are second-quarter free cash flow of negative $106.2 million, end-of-June inventory of $1.1201 billion, total debt of $1.8248 billion and the second quarter's $134.9 million goodwill impairment[28][25][26][43]. Long-lead instruments require materials and work in progress before shipment, customers are invoiced only after acceptance, and receivables are collected after delivery peaks; operating cash flow less capital spending gives free cash flow, which funds preferred and common dividends, with any shortfall covered by the revolving credit facility[34]. Lower forecasts for loss-making businesses trigger goodwill impairments, which reduce GAAP profit but consume no cash.

The third-quarter report needs to show whether cash turns positive without one-off payments. The specific checks are whether third-quarter free cash flow turns positive and reaches at least $30 million, how inventory and receivables change from the end of June, how the revolver balance and total debt move, and the result of the third-quarter interim goodwill test along with BSB's remaining goodwill. If third-quarter free cash flow is still negative with no one-off payments, the working capital drag is structural; if the interim test produces another impairment, forecasts for the loss-making businesses are still being cut.

Risks and Falsifiers

Tariff policy reversals are the first risk, and they affect both costs and revenue. After the Supreme Court struck down the IEEPA tariffs, Bruker sought refunds of tariffs paid in 2025 and the first quarter of 2026, and most requests had been approved by the end of June, but the refunds could still be reversed on appeal and other tariff measures remain in force or have been proposed[40]; the company's main production base is in Europe[17], tariffs raised product costs in 2025[45], and non-GAAP gross margin fell from 51.6% to 49.8%[21]. In the second quarter of 2026 net tariff benefits added about 200 basis points to operating margin and 6 cents to EPS, while refunds of tariffs passed on to customers, recorded as a reduction of revenue, cut organic growth by about 60 basis points[7]; US revenue was $891.3 million in 2025[35]. If the third-quarter report shows no new tariff costs and management keeps full-year margin guidance without flagging any reversal of tariff refunds, this risk has not materialized.

Currency is the second risk: about three-quarters of Bruker's revenue comes from outside the United States, while costs are concentrated in euros and Swiss francs[46]. Currency raised revenue by about 2.3% in 2025[35], but in August the company cut its 2026 full-year currency tailwind to revenue from about 1.5% to about 0.5%[2], and its debt is denominated in Swiss francs and euros[26]. If third-quarter currency effects stay within the full-year assumption management gave in August and full-year EPS guidance holds, this risk has not grown.

Continued cuts or delays in US academic and government funding are the third risk. The United States was 25.9% of 2025 revenue[35], a substantial portion of it from institutions that rely on NIH, NSF and DOE grants[36]; US academic and government revenue fell by more than $15 million year over year in the second quarter[7], and against full-year organic growth guidance of 1% to 2%, the first half came in at negative 0.8%[2]. If third-quarter organic revenue grows year over year, the BSI book-to-bill ratio stays above 1.0 and management reports stabilizing US academic orders, the current view of this risk would need revising.

Further slippage in semiconductor metrology deliveries is the fourth risk, and it affects the high-margin deliveries behind roughly $1 billion of fourth-quarter revenue and the full-year margin target[3]. About $20 million of revenue has already moved from the third quarter to the fourth, and at an EBIT margin of about 30%, each $20 million of revenue corresponds to about $6 million of operating income[8]; NANO second-quarter revenue was $261.3 million[29] with a 50.3% gross margin[32]. If third-quarter NANO revenue is at least $241.3 million and management confirms the fourth-quarter deliveries and its expectation of about $1 billion in revenue, this risk has not materialized.

Cost savings being offset by currency, inflation and acquisition costs is the fifth risk, and it bears directly on full-year margin expansion of 250 to 300 basis points and on EPS guidance. On full-year revenue of about $3.55 billion, each 100 basis points of operating margin equals about $35.5 million of non-GAAP operating income, or about $0.17 per share; of second-quarter non-GAAP operating income of $118.5 million, about 200 basis points of margin came from tariff benefits[30][7]. If the third-quarter non-GAAP operating margin is at least 12.5% and full-year guidance holds, this risk has not materialized.

Persistently negative cash flow is the sixth risk: delayed inventory build and collections on long-lead orders could leave the company relying on its revolver to pay dividends, while the loss-making spatial biology business takes further impairments. At the end of June inventory was $1.1201 billion, receivables $545.9 million and cash $184.9 million[25], with total debt of $1.8248 billion[26]; the preferred stock carries a $693.6 million liquidation preference and a 6.375% annual dividend rate[11], and BSB's remaining goodwill is $174.5 million[43]. If third-quarter free cash flow is at least $30 million, inventory is no higher than $1.120 billion and the interim test produces no new impairment, this risk has not materialized.

What to Watch Next

• US academic drag and order conversion: Second-quarter organic growth was 2.8%, BSI organic orders rose 10% and book-to-bill has been above 1.0 for four quarters. Watch whether third-quarter organic growth is positive and what management says about US academia and Asia Pacific; an organic decline attributed to demand would mean better orders have not yet covered US academic weakness.
• Semiconductor metrology deliveries: NANO second-quarter revenue was $261.3 million with a 50.3% gross margin. Watch whether third-quarter NANO revenue is at least $241.3 million and whether the $20 million ships in the fourth quarter; slippage into 2027 or a gross margin below 46% would weaken the current view.
• Cost savings versus tariffs: The second-quarter non-GAAP operating margin was 14.1% with EPS of $0.49, including about 200 basis points from tariffs. Watch where the margin lands relative to 12.0% and 14.1% and whether full-year guidance holds; a margin below 12.0% or an EPS guidance cut would weaken the current view.
• Working capital and goodwill: Second-quarter free cash flow was negative $106.2 million, inventory $1.1201 billion and total debt $1.8248 billion. Watch whether free cash flow reaches at least $30 million and whether another impairment is recorded; negative cash flow with no one-off payments, or a new interim-test impairment, would weaken the current view.

Conclusion

Bruker's business is driven by orders for and deliveries of high-end research instruments, and it is now at the stage where orders are recovering but revenue has not yet caught up. In 2025 revenue was $3.4365 billion, organic revenue fell 3.7%, and the non-GAAP operating margin fell from 15.4% to 12.6%[13][21]; in the second quarter of 2026 organic growth returned at 2.8% and the non-GAAP operating margin rose to 14.1%, but about 200 basis points of that came from tariff benefits recognized early[2][7]. Backlog rose to $2.7756 billion[27] while cash fell to $184.9 million[25], so the central open question is whether better orders and cost cuts can turn into revenue, margin and cash at the same time without relying on one-time gains.

After the second-quarter results, the third-party material available consisted mainly of brokers' adjusted views on the shares, restatements of company announcements and template-style earnings notes, and none offered independent analysis of the four questions above that could be checked. The article therefore cites no outside interpretation and does not treat this material as a shared market judgment; explanations of order conversion, semiconductor deliveries, margin composition and cash conversion currently come mainly from management's own statements and company filings.

From here, only a combination of observations would materially strengthen the current understanding: positive third-quarter organic revenue with the BSI book-to-bill ratio holding above 1.0, NANO revenue of at least $241.3 million, a non-GAAP operating margin excluding tariffs of at least 12.0%, and positive free cash flow without one-off payments. Conversely, if organic revenue falls on weak demand, semiconductor deliveries slip into 2027, the margin drops below 12%, or cash keeps flowing out alongside a new goodwill impairment, the current understanding would weaken and the fourth-quarter ramp behind full-year guidance would come into question.

Sources

[1] Drillr earning_call_calendar (updated 2026-10-19) · BRKRP earnings call 2026-10-29 · 2026-10-19 · Drillr earnings calendar

[2] BRKRP 8-K filed 2026-08-04 · 2Q26 results and FY2026 outlook · 2026-08-04 · 8-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526331511/brkr-ex99_1.htm

[3] BRKR earnings call 2026-08-04 · guidance · 2026-08-04 · earnings_call · https://www.fool.com/earnings/call-transcripts/2026/08/11/bruker-brkr-q2-2026-earnings-call-transcript/

[4] Drillr analyst_financial_estimates (updated 2026-10-19) · BRKR quarter ending 2026-09-30 · 2026-10-19 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[5] Drillr analyst_financial_estimates (updated 2026-10-19) · BRKR FY2026 · 2026-10-19 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[6] BRKR earnings call 2026-08-04 · management highlights · 2026-08-04 · earnings_call · https://www.fool.com/earnings/call-transcripts/2026/08/11/bruker-brkr-q2-2026-earnings-call-transcript/

[7] BRKR earnings call 2026-08-04 · analyst questions and answers · 2026-08-04 · earnings_call · https://www.fool.com/earnings/call-transcripts/2026/08/11/bruker-brkr-q2-2026-earnings-call-transcript/

[8] BRKR earnings call 2026-08-04 · segment performance · 2026-08-04 · earnings_call · https://www.fool.com/earnings/call-transcripts/2026/08/11/bruker-brkr-q2-2026-earnings-call-transcript/

[9] BRKRP 10-K filed 2026-02-27 · MD&A overview and headquarters · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[10] BRKRP 10-Q filed 2026-08-05 · mandatory convertible preferred issuance · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[11] BRKRP 10-Q filed 2026-08-05 · mandatory convertible preferred stock · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[12] BRKRP 10-K filed 2026-02-27 · business overview and segments · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[13] BRKRP 10-K filed 2026-02-27 · FY2025 income statement · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[14] BRKRP 10-K filed 2026-02-27 · workforce · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[15] BRKRP 10-K filed 2026-02-27 · major customers and competitors · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[16] BRKRP 10-K filed 2026-02-27 · FY2025 segment revenue and drivers · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[17] BRKRP 10-K filed 2026-02-27 · manufacturing and suppliers · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[18] BRKRP 10-K filed 2026-02-27 · sales channels, sales cycle and seasonality · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[19] BRKRP 10-K filed 2026-02-27 · backlog · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[20] BRKRP 10-Q filed 2026-08-05 · third-quarter 2026 segment reorganization · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[21] BRKRP 10-K filed 2026-02-27 · FY2025 consolidated and non-GAAP results · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[22] BRKRP 10-K filed 2026-02-27 · FY2025 segment gross and operating margins · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[23] BRKRP 10-K filed 2026-02-27 · FY2025 GAAP to non-GAAP operating income and free cash flow · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[24] BRKRP 8-K filed 2026-05-06 · 1Q26 results and reconfirmed guidance · 2026-05-06 · 8-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526207498/brkr-ex99_1.htm

[25] BRKRP 8-K filed 2026-08-04 · 2Q26 balance sheet · 2026-08-04 · 8-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526331511/brkr-ex99_1.htm

[26] BRKRP 10-Q filed 2026-08-05 · debt obligations · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[27] BRKRP 10-Q filed 2026-08-05 · remaining performance obligations · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[28] BRKRP 8-K filed 2026-08-04 · 2Q26 organic revenue and free cash flow · 2026-08-04 · 8-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526331511/brkr-ex99_1.htm

[29] BRKRP 8-K filed 2026-08-04 · 2Q26 revenue by segment and geography · 2026-08-04 · 8-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526331511/brkr-ex99_1.htm

[30] BRKRP 8-K filed 2026-08-04 · 2Q26 GAAP to non-GAAP reconciliation · 2026-08-04 · 8-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526331511/brkr-ex99_1.htm

[31] BRKRP 10-Q filed 2026-08-05 · 2Q26 SG&A and other charges · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[32] BRKRP 10-Q filed 2026-08-05 · 2Q26 gross margin by segment · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[33] BRKRP 10-Q filed 2026-08-05 · patent settlement payments · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[34] BRKRP 10-Q filed 2026-08-05 · liquidity and revolving facility · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[35] BRKRP 10-K filed 2026-02-27 · FY2025 revenue by geography and FX · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[36] BRKRP 10-K filed 2026-02-27 · U.S. academic funding risk · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[37] BRKRP 10-Q filed 2026-08-05 · 2Q26 segment revenue drivers and geography · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[38] BRKRP 10-Q filed 2026-08-05 · 2Q26 organic revenue drivers · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[39] BRKRP 10-Q filed 2026-08-05 · BSI Biosystems restructuring plan · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[40] BRKRP 10-Q filed 2026-08-05 · IEEPA tariff refunds · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[41] BRKRP 8-K filed 2026-08-04 · 2Q26 cash flow statement · 2026-08-04 · 8-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526331511/brkr-ex99_1.htm

[42] BRKRP 10-Q filed 2026-08-05 · 1H26 operating cash flow drivers · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[43] BRKRP 10-Q filed 2026-08-05 · 2Q26 goodwill impairment and sensitivity · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[44] BRKRP 10-Q filed 2026-08-05 · third-quarter interim goodwill test · 2026-08-05 · 10-Q · https://www.sec.gov/Archives/edgar/data/1109354/000119312526335226/brkr-20260630.htm

[45] BRKRP 10-K filed 2026-02-27 · tariff impact · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm

[46] BRKRP 10-K filed 2026-02-27 · foreign currency exposure · 2026-02-27 · 10-K · https://www.sec.gov/Archives/edgar/data/1109354/000119312526082523/brkr-20251231.htm